Trial Profile
Phase 2 Study of The Role of Pharmacologic Inhibition of TLR4 With E5564 on Glucose Metabolism in Insulin Resistant Subjects
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eritoran (Primary)
- Indications Insulin resistance; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Eritoran2
- 14 Sep 2018 Status changed from suspended to discontinued as the study drug expired
- 06 Sep 2017 Status changed from recruiting to suspended.
- 15 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.